Johnson & Johnson (JNJ)
228.17
+4.93 (2.21%)
Upcoming Events
Latest Headlines
Johnson & Johnson reports nipocalimab shows stronger response in Sjögren's patients
June 3, 2026 3:14 AM - StreetInsider
Johnson & Johnson's nipocalimab meets primary endpoint in lupus trial
June 3, 2026 12:04 AM - StreetInsider
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
June 3, 2026 12:04 AM - PR NewsWire
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
June 3, 2026 12:03 AM - PR NewsWire
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
May 31, 2026 8:30 AM - PR NewsWire
J&J prostate cancer drug shows positive trial results before surgery
May 31, 2026 8:28 AM - StreetInsider
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradi
May 31, 2026 8:27 AM - PR NewsWire
J&J's RYBREVANT plus LAZCLUZE shows 3.5-year survival in lung cancer study
May 29, 2026 2:00 PM - StreetInsider
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
May 29, 2026 2:00 PM - PR NewsWire
Johnson & Johnson TECVAYLI shows survival benefits in myeloma study
May 29, 2026 8:41 AM - StreetInsider
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
May 29, 2026 8:18 AM - PR NewsWire
FDA approves expanded TREMFYA label for joint damage prevention
May 28, 2026 7:10 PM - StreetInsider
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
May 28, 2026 7:10 PM - PR NewsWire
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
May 27, 2026 4:22 PM - BizWire
Form SD JOHNSON & JOHNSON
May 27, 2026 4:16 PM - SEC Filing
DePuy Synthes signs exclusive distribution deal with CGBIO for bone graft
May 26, 2026 8:03 AM - StreetInsider
DePuy Synthes acquires radiofrequency tracking technology for joint surgery
May 26, 2026 8:01 AM - StreetInsider
DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction Portfolio
May 26, 2026 8:01 AM - BizWire
DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS
May 26, 2026 8:00 AM - BizWire
FDA approves accord Biopharma's Immgolis, a biosimilar to Simponi
May 15, 2026 2:58 PM - StreetInsider
Johnson & Johnson survey finds bladder cancer treatments impact patient quality of life
May 14, 2026 4:01 PM - StreetInsider
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
May 14, 2026 4:01 PM - PR NewsWire
Form 13F-HR JOHNSON & JOHNSON For: Mar 31
May 13, 2026 4:30 PM - SEC Filing
JNJ gets Wall Street boost as blockbuster drug bets ignite growth hopes
May 13, 2026 10:56 AM - StreetInsider
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
May 13, 2026 8:30 AM - Globe NewsWire
Leerink Partners Upgrades Johnson & Johnson (JNJ) to Outperform
May 13, 2026 6:10 AM - StreetInsider
Johnson & Johnson launches Shockwave C2 Aero coronary catheter globally
May 12, 2026 7:45 AM - StreetInsider
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
May 12, 2026 7:45 AM - BizWire
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 11, 2026 4:34 PM - BizWire
Johnson & Johnson presents neuropsychiatry data at medical conferences
May 11, 2026 8:01 AM - StreetInsider
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
May 11, 2026 8:00 AM - PR NewsWire
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
May 7, 2026 8:00 AM - PR NewsWire
Protagonist Therapeutics (PTGX) PT Raised to $137 at Citizens
May 6, 2026 4:28 AM - StreetInsider
Johnson & Johnson's TREMFYA shows efficacy in perianal fistulizing Crohn's
May 5, 2026 8:05 AM - StreetInsider
Johnson & Johnson reports positive phase 2b results for experimental IBD therapy
May 5, 2026 8:05 AM - StreetInsider
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
May 5, 2026 8:05 AM - PR NewsWire
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 5, 2026 8:05 AM - PR NewsWire
Johnson & Johnson reports clinical trial results for robotic surgery system
May 5, 2026 7:00 AM - StreetInsider
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
May 5, 2026 7:00 AM - BizWire
Form 4 JOHNSON & JOHNSON For: May 01 Filed by: REED JOHN C
May 4, 2026 4:59 PM - SEC Filing
Johnson & Johnson presents CAPLYTA analysis for depression treatment
May 4, 2026 8:03 AM - StreetInsider
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
May 4, 2026 8:00 AM - PR NewsWire
Form SCHEDULE 13G JOHNSON & JOHNSON Filed by: VANGUARD CAPITAL MANAGEMENT LLC
May 1, 2026 9:12 AM - SEC Filing
Johnson & Johnson names Ryan Koors as VP of investor relations
April 30, 2026 8:02 AM - StreetInsider
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
April 30, 2026 8:02 AM - BizWire
Form 8-K JOHNSON & JOHNSON For: Apr 23
April 28, 2026 6:01 AM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Woods Eugene A.
April 27, 2026 6:24 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: West Nadja
April 27, 2026 6:22 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: WEINBERGER MARK A
April 27, 2026 6:17 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Pinto Daniel E
April 27, 2026 6:14 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: MORIKIS JOHN G
April 27, 2026 6:12 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: McClellan Mark B.
April 27, 2026 6:07 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Joly Hubert
April 27, 2026 6:06 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Johnson Paula A
April 27, 2026 6:01 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: HEWSON MARILLYN A
April 27, 2026 5:49 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Doudna Jennifer A
April 27, 2026 5:43 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Beckerle Mary C
April 27, 2026 5:38 PM - SEC Filing
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference
April 27, 2026 4:33 PM - BizWire
FDA grants priority review to J&J's IMAAVY for rare blood disorder
April 27, 2026 8:03 AM - StreetInsider
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
April 27, 2026 8:03 AM - PR NewsWire
Johnson & Johnson (JNJ) to start marketing 4 meds on TrumpRX - CBS
April 24, 2026 4:23 PM - StreetInsider
Johnson & Johnson to acquire medical device firm Atraverse Medical
April 24, 2026 8:38 AM - StreetInsider
Form 10-Q JOHNSON & JOHNSON For: Mar 29
April 22, 2026 4:03 PM - SEC Filing
Johnson & Johnson IMAAVY shows sustained disease control for myasthenia gravis
April 22, 2026 8:07 AM - StreetInsider
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
April 22, 2026 8:06 AM - PR NewsWire
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
April 21, 2026 4:22 PM - BizWire
Johnson & Johnson launches CARTOSOUND SONATA at HRS 2026 medical conference
April 21, 2026 7:45 AM - StreetInsider
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
April 21, 2026 7:45 AM - BizWire
Johnson & Johnson (JNJ) PT Raised to $230 at Freedom Broker
April 20, 2026 3:56 PM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $266 at Guggenheim
April 20, 2026 6:51 AM - StreetInsider
The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
April 16, 2026 11:00 AM - StreetInsider
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
April 15, 2026 4:12 PM - BizWire
Johnson & Johnson (JNJ) PT Raised to $254 at BofA Securities
April 15, 2026 9:29 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $260 at JPMorgan
April 15, 2026 8:40 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $283 at Morgan Stanley
April 15, 2026 8:35 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $263 at Wells Fargo
April 15, 2026 8:06 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $355 at Argus
April 15, 2026 7:10 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ), 'continue to see JNJ as one of our Top Picks'
April 15, 2026 6:53 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $250 at Stifel on Beat and Raise Performance
April 15, 2026 6:50 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $255 at Barclays
April 15, 2026 5:57 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $251 at Bernstein SocGen Group
April 15, 2026 5:25 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $265 at RBC Capital
April 14, 2026 5:09 PM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Apr 14
April 14, 2026 7:35 AM - SEC Filing
Johnson & Johnson beats estimates, raises 2026 guidance
April 14, 2026 6:45 AM - StreetInsider
J&J tops first-quarter profit estimates even as Stelara sales plunge
April 14, 2026 6:27 AM - StreetInsider
Johnson & Johnson (JNJ) Raises Quarterly Dividend 3.1% to $1.34; 2.3% Yield
April 14, 2026 6:23 AM - StreetInsider
Johnson & Johnson (JNJ) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY Guidance
April 14, 2026 6:22 AM - StreetInsider
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
April 14, 2026 6:21 AM - BizWire
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
April 14, 2026 6:20 AM - BizWire
Johnson & Johnson Q1 earnings preview: analysts eye pharma strength, legal overhang
April 14, 2026 2:00 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 1.5 calls to 1 put into quarter results
April 13, 2026 11:08 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 1 call to 1.1 puts into quarter results
April 13, 2026 5:05 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $267 at Morgan Stanley
April 10, 2026 8:16 AM - StreetInsider
Johnson & Johnson presents clinical data for TECNIS PureSee lens at ASCRS
April 10, 2026 8:01 AM - StreetInsider
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
April 10, 2026 8:00 AM - BizWire
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value
April 9, 2026 8:30 AM - StreetInsider
TD Cowen Assumes Johnson & Johnson (JNJ) at Buy
April 8, 2026 4:43 AM - StreetInsider
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
April 7, 2026 9:01 AM - BizWire
Johnson & Johnson launches VARIPULSE Pro in Europe with CE Mark approval
April 7, 2026 8:05 AM - StreetInsider
Johnson & Johnson receives permanent billing code for bladder cancer treatment
April 1, 2026 12:52 PM - StreetInsider
Royalty Pharma partners with J&J on $500M drug development deal
March 30, 2026 7:16 AM - StreetInsider
J&J reports one-year ICOTYDE psoriasis treatment data shows sustained results
March 30, 2026 4:21 AM - StreetInsider
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
March 28, 2026 10:00 AM - PR NewsWire
Form SCHEDULE 13G/A JOHNSON & JOHNSON Filed by: VANGUARD GROUP INC
March 26, 2026 10:05 AM - SEC Filing
Nanobiotix stock jumps on takeover report involving J&J
March 25, 2026 7:26 AM - StreetInsider
TuHURA names former J&J oncology executive as chief medical officer
March 23, 2026 7:45 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
March 19, 2026 6:33 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $234 at Barclays
March 19, 2026 3:36 AM - StreetInsider
Form 13F-HR/A JOHNSON & JOHNSON For: Dec 31
March 18, 2026 11:57 AM - SEC Filing
Form 13F-HR/A JOHNSON & JOHNSON For: Sep 30
March 18, 2026 11:38 AM - SEC Filing
BofA Securities remains Neutral on Johnson & Johnson (JNJ): early Ico approval was 'modest upside'
March 18, 2026 11:26 AM - StreetInsider
Morgan Stanley stays Overweight on Johnson & Johnson (JNJ) following 'expected positive' Ico approval
March 18, 2026 11:23 AM - StreetInsider
Wolfe Research stays Outperform on Johnson & Johnson (JNJ): focus shifts to upcoming h2h trial data
March 18, 2026 8:43 AM - StreetInsider
FDA approves Johnson & Johnson's ICOTYDE for plaque psoriasis treatment
March 18, 2026 7:50 AM - StreetInsider
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
March 18, 2026 7:50 AM - PR NewsWire
Johnson & Johnson wins new trial on punitive damages in baby powder case
March 17, 2026 3:03 PM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $280 at UBS
March 17, 2026 8:30 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $280 at HSBC
March 17, 2026 3:39 AM - StreetInsider
J&J reports 89% response rate in bladder cancer drug trial
March 13, 2026 12:36 PM - StreetInsider
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
March 13, 2026 12:35 PM - PR NewsWire
Form 4 JOHNSON & JOHNSON For: Mar 04 Filed by: HEWSON MARILLYN A
March 12, 2026 9:32 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Mar 10 Filed by: Pinto Daniel E
March 12, 2026 8:40 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Mar 10 Filed by: Woods Eugene A.
March 12, 2026 8:37 PM - SEC Filing
Johnson & Johnson receives FDA approval for TECNIS PureSee eye lens
March 12, 2026 8:00 AM - StreetInsider
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
March 12, 2026 8:00 AM - BizWire
Form ARS JOHNSON & JOHNSON For: Dec 28
March 11, 2026 6:23 AM - SEC Filing
Form DEFA14A JOHNSON & JOHNSON
March 11, 2026 6:18 AM - SEC Filing
Form DEF 14A JOHNSON & JOHNSON For: Mar 11
March 11, 2026 6:15 AM - SEC Filing
Full Article List
